ArticleEndocrine2025
MicroRNA signatures of invasiveness in PitNETs: a focus on miR-186-5p, miR-191-5p, miR-454-3p, and miR-590-5p.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic kidney disease as a potential risk factor for pituitary hormone dysregulation: a review of the underlying mechanisms.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposePituitary neuroendocrine tumors (PitNETs) are usually benign tumors of the anterior lobe of the pituitary gland, but some exhibit invasive behavior. Research increasingly highlights microRNAs (miRs) as promising markers of PitNET invasiveness. Our study aimed to identify and validate miR expression differences in invasive versus noninvasive PitNETs, independent of their hormonal activity.
methodsWe evaluated the global expression of 754 miRs in 12 human PitNETs (6 invasive and 6 noninvasive) using TaqMan Low-Density Array cards. We further validated the expression of the 9 most dysregulated miRs in an expanded cohort of 75 human PitNETs using quantitative PCR. Moreover, we examined the expression of 6 mRNAs, for which our miRs had potential binding sites. This was followed by in vitro functional validation using colony formation, migration, and invasion assays in the RC-4B/C rat pituitary adenoma cell line.
resultsOf the 754 miRs, 22 showed significant dysregulation in the initial cohort. In the expanded cohort (n = 75) miR-191-5p was significantly downregulated in invasive PitNETs (p = 0.0062**) across all hormonal activity types, while miR-186-5p was upregulated in gonadotrophs and somatotrophs (p = 0.0264*). In vitro experiments revealed that miR-454-3p and miR-590-5p increased invasiveness of the model cell line RC-4B/C. Coexpression analysis revealed associations between specific miRs and targeted genes such as PTEN, TIMP2, and TGFB1, which may suggest their potential role in PitNETs pathogenesis. Yet, negative correlation among invasive tumors between mir-26a-5p and PTEN expression may suggest its regulatory mechanisms.
conclusionsThis study identifies miR-191-5p and miR-186-5p as potential biomarkers for invasive PitNETs, while functional studies highlight miR-454-3p and miR-590-5p as potential contributors to tumor invasiveness. Correlations with target genes PTEN, TIMP2, and TGFB1 suggest miRs-mediated regulatory pathways in PitNET pathogenesis. These findings provide insights into the molecular mechanisms underlying PitNET invasiveness, with implications for biomarker development and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.